

Saturday (22.10.2022)	Sunday (23.10.2022)	Monday (24.10.2022)	
	<b>07:30-09:00 Interactive Case Discussion</b> <i>(Faculty: T. Illidge, J. Zijlstra)</i> <ul style="list-style-type: none"> <li>• Presentation of difficult and controversial Hodgkin Lymphoma cases with a focus on interaction and discussion               <ul style="list-style-type: none"> <li>◦ Greyzone Lymphoma <i>(L. Plinczés)</i></li> <li>◦ Anti-PD1 Failure <i>(G. Collins)</i></li> <li>◦ COVID19 immunity in lymphoma <i>(S. Mellingshoff)</i></li> <li>◦ Primary progressive HL <i>(A. S. Jacob)</i></li> </ul> </li> </ul>	<b>07:30-09:00 Advanced Stages</b> <i>(O. Casasnovas, J. Radford)</i> <ul style="list-style-type: none"> <li>• Why I recommend... BV-AVD <i>(R. Advani)</i>, PET-guided ABVD <i>(A. Fossá)</i>, PET-guided eBEACOPP <i>(P. Borchmann)</i></li> <li>• Discussion forum <i>(Patient: J. Richardson, Nurse: S. Wells, Physician: M. Dreyling)</i></li> <li>• WS Report: Learning through International Collaboration <i>(P. Borchmann, A. J. Moskowitz)</i></li> <li>• Oral Abstract Presentations</li> </ul>	07:30
<b>08:45-10:15 Seminars and Workshops</b> <ul style="list-style-type: none"> <li>• WS: Living beyond Lymphoma <i>(F. van Leeuwen, L. Specht)</i></li> <li>• Seminar: The HL Microenvironment <i>(A. Rosenwald, M. Shipp)</i></li> <li>• Joint EHA-ISHL Symposium <i>(P. Borchmann, M. Dreyling)</i></li> <li>• WS: PET beyond Deauville <i>(S. Barrington, M. Hutchings, C. Kobe)</i></li> <li>• WS: Innovation for Older Patients <i>(P. Bröckelmann, A. Fossá)</i></li> </ul>	<b>Coffee Break</b> <b>09:15-10:15 Emerging Cellular Therapies - a Role in HL?</b> <i>(S. Ansell, P. Borchmann)</i> <ul style="list-style-type: none"> <li>• Cellular Therapy in HL <i>(B. Savoldo)</i></li> <li>• Design and optimization of CD30 CARs for cHL <i>(C. Quintarelli)</i></li> <li>• Emerging indications for cellular therapy <i>(P. Borchmann)</i></li> </ul>	<b>Coffee Break</b> <b>09:15-10:15 Special Situations in HL</b> <i>(R. Hoppe, M. J. Kersten)</i> <ul style="list-style-type: none"> <li>• HL in Pregnancy <i>(D. Dierickx)</i></li> <li>• HIV-positive HL <i>(D. Balocchi)</i></li> <li>• alloSCT in the era of anti-PD1 <i>(A. Sureda)</i></li> </ul>	09:00 09:15
<b>Coffee Break</b> <b>10:30-12:00 Seminars and Workshops</b> <ul style="list-style-type: none"> <li>• Seminar: Radiotherapy <i>(C. Baues, J. Yahalom)</i></li> <li>• Seminar: Learning from Pediatric HL <i>(J. Friedberg, C. Mauz-Körholz)</i></li> <li>• WS: Bringing Liquid Biopsy to Patients <i>(S. Borchmann, D. Rossi)</i></li> <li>• WS: NPLHL <i>(M. Binkley, D. Eichenauer, S. Hartmann)</i></li> </ul>	<b>Coffee Break</b> <b>10:30-12:00 Living beyond Lymphoma</b> <i>(F. van Leeuwen, J. Radford)</i> <ul style="list-style-type: none"> <li>• Towards Lung Cancer Screening in Hodgkin Lymphoma Survivors <i>(K. Linton)</i></li> <li>• GHSg data on fertility, fatigue and social reintegration and the ongoing EMBrAcE study <i>(K. Behringer)</i></li> <li>• WS Report: Living beyond Lymphoma <i>(F. van Leeuwen, L. Specht)</i></li> <li>• Oral Abstract Presentations</li> </ul>	<b>Coffee Break</b> <b>10:30-12:00 Genomics, Biology &amp; Microenvironment</b> <i>(W. Klapper, R. Küppers)</i> <ul style="list-style-type: none"> <li>• Biological Classification of HL by Liquid Biopsy <i>(S. Borchmann)</i></li> <li>• Single Cell Transcriptomics of HL <i>(C. Steidl)</i></li> <li>• WS Report: Bringing Liquid Biopsy to Patients <i>(S. Borchmann, D. Rossi)</i></li> <li>• Oral Abstract Presentations</li> </ul>	10:15 10:30
<b>Coffee Break</b> <b>12:15-13:45 Opening paths to the next chapters of lymphoma treatment by BeiGene</b> <i>(P. Borchmann)</i> <ul style="list-style-type: none"> <li>• Welcome and Introduction to the topic <i>(P. Borchmann)</i></li> <li>• Hodgkin's lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma <i>(P. Bröckelmann)</i></li> <li>• The challenge of the older patient in lymphoma therapy <i>(G. Collins)</i></li> <li>• New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies <i>(P. L. Zinzani)</i></li> </ul>	<b>Coffee Break</b> <b>12:15-13:15 Checkpoint inhibition in HL State of the art and future perspectives by MSD</b> <i>(P. Borchmann)</i> <ul style="list-style-type: none"> <li>• Firstline therapy of classical Hodgkin Lymphoma - How can immunotherapy improve outcome? <i>(P. Borchmann)</i></li> <li>• The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma <i>(B. v. Tresckow)</i></li> <li>• Strategies to enhance checkpoint inhibition <i>(P. Bröckelmann)</i></li> </ul>	<b>Coffee Break</b> <b>12:15-13:45 Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma by Takeda</b> <i>(G. Collins, A. Herrera, P. L. Zinzani)</i> <ul style="list-style-type: none"> <li>• Hot Off the Press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHOLON-1</li> <li>• Bridging the gap: Balancing efficacy and toxicity in three challenging case studies</li> <li>• Audience Q&amp;A</li> <li>• Summary and close</li> </ul>	12:00 12:15
<b>Coffee Break</b> <b>14:00-15:30 Early Stages</b> <i>(M. André, H.-T. Eich)</i> <ul style="list-style-type: none"> <li>• Standard treatment of early-stage HL <i>(J. Radford)</i></li> <li>• Individual risk assessment of RT in HL <i>(R. Hoppe)</i></li> <li>• WS Report: NPLHL <i>(M. Binkley, D. Eichenauer, S. Hartmann)</i></li> <li>• Oral Abstract Presentations</li> </ul>	<b>Coffee Break</b> <b>14:00-15:30 Older and Frail Patients</b> <i>(R. Cordoba, A. Evens)</i> <ul style="list-style-type: none"> <li>• Managing an Older Lymphoma Patient <i>(R. Cordoba)</i></li> <li>• Treatment Allocation in Older HL Patients <i>(A. Evens)</i></li> <li>• WS Report: Innovation for Older patients <i>(A. Fossá, P. Bröckelmann)</i></li> <li>• Oral Abstract Presentations</li> </ul>	<b>Coffee Break</b> <b>14:00-15:30 Relapsed / Refractory HL</b> <i>(R. Advani, C. H. Moskowitz)</i> <ul style="list-style-type: none"> <li>• 1<sup>st</sup> Relapse of HL <i>(C. H. Moskowitz)</i></li> <li>• Novel developments in R / R HL <i>(G. Collins)</i></li> <li>• WS Report: PET beyond Deauville, <i>(S. Barrington, M. Hutchings, C. Kobe)</i></li> <li>• Oral Abstract Presentations</li> </ul>	13:45 14:00
<b>Coffee Break</b> <b>16:00-17:30 CAR T cell therapy in B Cell NHL: Status quo and future perspectives by BMS</b> <i>(P. Cramer, C. Scheid)</i> <ul style="list-style-type: none"> <li>• Status quo of CAR T cell therapy for r/r DLBCL <i>(P. Borchmann)</i></li> <li>• New perspective for the treatment of r/r CLL <i>(P. Cramer)</i></li> <li>• CAR T - Lessons Learned <i>(C. Scheid)</i></li> </ul>	<b>Coffee Break</b> <b>16:00-17:30 Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory HL by Takeda</b> <ul style="list-style-type: none"> <li>• Welcome and introduction <i>(A. Sureda)</i></li> <li>• Navigating Complex Treatment Decisions in R/R HL <i>(T. Vassilakopoulos)</i></li> <li>• Challenging Case Study #1 <i>(M. Hutchings)</i></li> <li>• Learning from Real-World Evidence to Inform Treatment Decisions in R/R HL <i>(A. Sureda)</i></li> <li>• Challenging Case Study #2 <i>(M. Hutchings)</i></li> </ul>	<b>Closing Remarks with Conference Highlights</b> <i>(R. Advani)</i> <b>16:00-16:30 Farewell</b>	15:30 16:00
<b>Coffee Break</b> <b>18:00 Opening and Award Ceremony</b> <ul style="list-style-type: none"> <li>• Keynote Lecture tbd <i>(U. Şahin)</i></li> </ul>	<b>Coffee Break</b> <b>18:00-19:30 Immunotherapy</b> <i>(P. Armand, P. Zinzani)</i> <ul style="list-style-type: none"> <li>• New findings and new challenges since last ISHL <i>(S. Ansell)</i></li> <li>• Oral Abstract Presentations</li> <li>• Vision Corner               <ul style="list-style-type: none"> <li>◦ Stimulus Talks <i>(C. Steidl, P. Bröckelmann, G. Collins)</i></li> <li>◦ Discussion <i>(Chairs: P. Armand, P. Zinzani, Discussants: C. Steidl, P. Bröckelmann, G. Collins)</i></li> </ul> </li> </ul>		17:30 18:00
<b>19:00-20:30 Poster Session with Welcome Reception</b>			19:00 19:30
			20:00